Treatment of Refractory Hyperlipidemia Using Double Filtration Plasmapheresis System(DFPP)

方艺,丁小强,陈利明,滕杰,钟一红,傅辰生,邹建洲
DOI: https://doi.org/10.3969/j.issn.1008-6358.2004.06.052
2003-01-01
Abstract:Objective To investigate the acute effects of single DFPP treatment for non-familial refractory hyperlipidemia. Methods Twenty non-familial refractory hyperlipidemia patients had taken DFPP therapy. Fcurteen of them either had both hypercholesterolemia (totol cholesterol ≥ 6.8mmol/L) and high level of LDL (LDL ≥ 3.1mmol/L) or had both hypertriglyceridemia (triglyceride≥2mmol/l) and high level of LDL. Blood samples were collected from the patients and the serum level of total cholesterol, triglyceride, low density lipoprotein (LDL), Apolipoprotein A (Apo-A), Apolipoprotein B (Apo-B), Lipoprotein(a) (Lp(a)) and fibrinogen were tested just before and after the treatment. Eleven patients had complete recordings. Results The average age of the 11 patients was 45.25±8.33 years old. Total substitute volume was 4183±667 (3000~5000)ml. After treatments there were significant reduction of TC, LDL, Apo(A), Apo(B), Lp(a),HDL and fibrinogen. Those parameters were decreased, from (6.86±1.17)mmol/L to (3.42±0.63)mmol/L, (3.92±2.13)mmol/L to (3.57±1.82)mmol/L, (4.03±0.86)mmol/L to (1.13±0.66)mmol/L, (1.34 ± 0.37)g/L to (0.85 ± 0.30)g/L、 (1.34 ± 0.57)g/L to (0.70±0.34)g/L,(176.14±75.53)mg/L to (98.43±44.08)mg/L, (1.03±0.28)mmol/L to (0.68±0.22)mmol/L, (263.6±86.49)mg/dl to (154.88±44.12)mg/dl (P0.05, P0.01) respectively。After each treatment the acute reduction in TC, TG, LDL, Apo(A), Apo(B) and fibrinogen was 51%, 72%, 32%, 44%, 40% and 43% respectively. There was no obvious side effect during each therapy. Conclusion DFPP can significantly ameliorate the disorders of lipid metabolism. Patients' serum lipids can be reduced into normal range after single treatment, contributing to reducing the drug dosage and side effects. [
What problem does this paper attempt to address?